<DOC>
	<DOCNO>NCT00560287</DOCNO>
	<brief_summary>Non-invasive mechanical ventilation ( NIV ) increasingly use treatment chronic hypercapnic respiratory failure . Its use patient affect chronic obstructive pulmonary disorder still controversial , study perform restrictive thoracic disorder ( RTD ) , particular neuromuscular patient , suggest alleviation symptom chronic hypoventilation short term , two small study survival prolong . In terminal phase disease , respiratory muscle become weaker likely operator need frequently adjust level inspiratory pressure attempt guarantee adequate tidal volume , alveolar hypoventilation may avoid . Theoretically use volume assist ventilation may overpass problem frequent variation setting , since provision fix tidal volume may always guarantee adequate alveolar ventilation . The primary aim multicenter randomize study evaluate clinical efficacy , patient ' tolerance quality life frequency change setting group patient SLS initial chronic respiratory failure undergo long-term NIV Pressure Support Ventilation Volume Assisted Ventilation .</brief_summary>
	<brief_title>Non-Invasive Ventilation Amyotrophic Lateral Sclerosis</brief_title>
	<detailed_description>Background Non-invasive mechanical ventilation ( NIV ) increasingly use treatment chronic hypercapnic respiratory failure . Its use patient affect chronic obstructive pulmonary disorder still controversial , study perform restrictive thoracic disorder ( RTD ) , particular neuromuscular patient , suggest alleviation symptom chronic hypoventilation short term , two small study survival prolonged . As matter fact recent Cochrane review state `` long-term mechanical ventilation offer therapeutic option patient chronic respiratory failure due neuromuscular disease '' . Recurrent episodes nocturnal desaturation especially REM sleep may deeply influence prognosis patient affect disorder ( i.e . ALS ) , often associate hypercapnia , correction nocturnal hypoventilation seem major goal achieve ventilatory treatment . A recent randomized control trial show ALS without severe bulbar dysfunction , NIV improve survival maintenance , improvement , quality life , include sleep quality . The survival benefit NIV group much great currently available neuroprotective therapy , like riluzole . Most study perform RTD disorder perform use pressure assist mode ( i.e Pressure Support Ventilation ) , suppose well tolerance patient easy setting operator , even though never scientifically proven . In terminal phase disease , respiratory muscle become weaker likely operator need frequently adjust level inspiratory pressure attempt guarantee adequate tidal volume , alveolar hypoventilation may avoid . Theoretically use volume assist ventilation may overpass problem frequent variation setting , since provision fix tidal volume may always guarantee adequate alveolar ventilation . The primary aim multicenter randomize study evaluate clinical efficacy , patient ' tolerance quality life frequency change setting group patient SLS initial chronic respiratory failure undergo long-term NIV Pressure Support Ventilation Volume Assisted Ventilation . Aim Project The primary aim project evaluate clinical efficacy , patient ' tolerance quality life frequency change setting group patient SLS initial chronic respiratory failure undergo long-term NIV Pressure Support Ventilation Volume Assisted Ventilation . â€¢ Enrollment criterion : Patients diagnosis ALS one follow sign : 1 ) Vital Capacity &lt; 50 % predict 2 ) Maximal Inspiratory Pressure ( MIP ) &lt; 60 % predict 3 ) polygraphic sign nocturnal hypoventilation daytime symptom . - The patient randomize receive NIV one follow mode : 1 ) Pressure Support Ventilation inspiratory pressure set accord patient 's tolerance order achieve expire tidal volume &gt; 6 ml/Kg &lt; 8ml/Kg . The back-up rate set 10 breaths/min . 2 ) Volume assist ventilation back-up rate 10 breaths/min tidal volume set achieve expire tidal volume &gt; 6 ml/Kg &lt; 8ml/Kg</detailed_description>
	<mesh_term>Sclerosis</mesh_term>
	<mesh_term>Motor Neuron Disease</mesh_term>
	<mesh_term>Amyotrophic Lateral Sclerosis</mesh_term>
	<mesh_term>Respiratory Insufficiency</mesh_term>
	<criteria>Patients diagnosis ALS one follow sign : Vital Capacity &lt; 50 % predict A Maximal Inspiratory Pressure ( MIP ) &lt; 60 % predict Polygraphic sign nocturnal hypoventilation daytime symptom . Life expectancy &gt; 12 month Any comorbidity Acute Respiratory Failure</criteria>
	<gender>All</gender>
	<minimum_age>20 Years</minimum_age>
	<maximum_age>80 Years</maximum_age>
	<verification_date>March 2010</verification_date>
	<keyword>Amyotrophic Lateral Sclerosis</keyword>
	<keyword>Non-invasive ventilation</keyword>
	<keyword>Chronic Respiratory Failure</keyword>
</DOC>